A Competitive Analysis of the Global Asthma and COPD Therapeutics Market
DUBLIN, Nov. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "A Competitive Analysis of the Global Asthma and COPD Therapeutics Market " report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
The research service assesses marketed and investigatory products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.
Key Findings:
- Chronic obstructive pulmonary disorder (COPD) is the third leading cause of death in the United States, and is in fourth place in Europe and the rest of the world.
- An estimated million people are affected by COPD globally. By 2020, COPD is projected to be the third leading cause of death globally.
- Limited communication between medical practitioners and patients limits early diagnosis of the disease.
- It is estimated that only XX% of smokers detect the onset of COPD symptoms and seek medical advice and treatment.
- Bronchodilators, anti-inflammatories, and combination therapies are prime segments used in evaluating asthma and COPD therapeutics.
- Combination therapies such as Symbicort Turbuhaler, Relvar Ellipta, and Anoro Ellipta show promising market acceptance due to increased clinical benefits of higher drug efficacy, especially in patients with increased disease severity.
- Bronchodilators are widely used to manage mild to moderate symptoms associated with COPD.
- Patent expiration of blockbuster drugs such as Advair (known as Seretide in the European Union) widen pipeline investment opportunities to meet therapeutic demand.
Key Topics Covered:
1. Executive Summary
2. Methodology and Scope
3. Market Overview
4. Asthma and COPD Competitive Landscape
5. Event Timelines
6. Product DashboardsMarketed, Approved, and Phase 3 Products
7. Conclusions
8. Appendix
9. The Story
For more information visit http://www.researchandmarkets.com/research/fv85j8/a_competitive
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article